Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
June 14, 2018 10:12 ET | Rafael Pharmaceutical Inc.
Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways...
Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-term Survival Outcomes
May 17, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...
Geron-logo-black-xsmall.png
Geron Announces Oral Presentation at European Hematology Association Congress
May 17, 2018 09:05 ET | Geron Corporation
MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET | Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET | Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Achillion-Logo-150 (4).jpg
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
June 10, 2016 03:30 ET | Achillion Pharmaceuticals, Inc.
-  Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471  - -  Results support initiation...
Achillion-Logo-150 (4).jpg
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
May 19, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN,...
Edgewaterlogo.jpg
Edgewater Ranzal Introduces Ranzal Healthcare Analytics
August 25, 2015 08:30 ET | Edgewater Technology, Inc.
WHITE PLAINS, N.Y., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Edgewater Technology-Ranzal LLC, (Edgewater Ranzal), a wholly-owned subsidiary of Edgewater Technology, Inc. (NASDAQ:EDGW) and Platinum level...